Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 11

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. Nov 26, 2011; 3(11): 351-358
Published online Nov 26, 2011. doi: 10.4330/wjc.v3.i11.351

Table 2 Factors associated with an increased risk of bleeding

Author
Age > 65-70 yr
Female gender
CYP2C9 and/or VKORC1 gene polymorphism
Higher intensity of anticoagulation (i.e., INR > 4.5)
Labile INR (i.e., TTR < 60%)
Early 90 d of anticoagulation
History of bleeding
Comorbidities (i.e., hypertension, malignancy, liver and/or renal and/or cardiac failure)
Comedications (i.e., antiplatelet agents, non-steroidal anti-inflammatory drugs)

INR: International normalized ratio; TTR: Time within the therapeutic range.

Citation: Rubboli A, Becattini C, Verheugt FW. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol 2011; 3(11): 351-358
URL: https://www.wjgnet.com/1949-8462/full/v3/i11/351.htm
DOI: https://dx.doi.org/10.4330/wjc.v3.i11.351

Rubboli A, Becattini C, Verheugt FW. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol 2011; 3(11): 351-358 [PMID: 22125670 DOI: 10.4330/wjc.v3.i11.351]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.